Academic Journal
Biomimetic Nanocarriers for Glioblastoma Therapy: Translational Advances and Strategic Challenges.
| Τίτλος: | Biomimetic Nanocarriers for Glioblastoma Therapy: Translational Advances and Strategic Challenges. |
|---|---|
| Συγγραφείς: | Jain, Bhawana1,2 (AUTHOR), Sanwaria, Sunita2,3 (AUTHOR), Hadap, Arti2,3,4 (AUTHOR), Joni, I Made2,4,5 (AUTHOR), Febrida, Renny2,5,6 (AUTHOR), Ruslami, Rovina6,7 (AUTHOR), Purnama, Irwan7,8,9 (AUTHOR), Singh, Deoraj8,10 (AUTHOR), Panatarani, Camellia2,5,9 (AUTHOR) c.panatarani@phys.unpad.ac.id |
| Πηγή: | Cancers. Sep2026, Vol. 18 Issue 18, p2982. 34p. |
| Θεματικοί όροι: | *Therapeutic use of biomedical materials, *Glioma treatment, *Gene therapy, *Immunogenetics, *Biotechnology, *Immunotherapy, *Blood-brain barrier, *Cell physiology, *Drug delivery systems, *Drug stability, *Individualized medicine, *Bioavailability, *Nanoparticles, *Phagocytosis |
| Περίληψη: | Simple Summary: Glioblastoma (GBM) is the most aggressive and common brain tumor, highly resistant to conventional treatment, largely due to the blood brain barrier (BBB) limiting effective drug delivery. Biomimetic nanoparticles (BNPs) offer a promising therapeutic approach by mimicking biological structures to improve drug stability, BBB penetration, and tumorspecific targeting while reducing systemic toxicity. BNPs can be engineered from diverse biomaterials, including cell membranes, liposomes, and polymeric systems. Preclinical and early clinical studies show BNPs enhance drug bioavailability and therapeutic efficacy. However, challenges remain stability, immunogenicity, regulatory approval, and scalable production hindering clinical translation. This review highlights recent BNPs advances, targeting strategies, and limitations, while exploring integration with immunotherapy and gene therapy to enable more personalized, effective GBM treatment approaches. Glioblastoma (GBM) is the most aggressive and common type of brain tumor, characterized by rapid growth and infiltration, as well as high resistance to conventional treatments. Given the persistent challenge posed by the bloodbrain barrier (BBB) to effective drug delivery, a shift in therapeutic strategies is required. Biomimetic nanocarriers (BNCs) represent a promising approach for the targeted treatment of malignant brain tumors. By replicating biological structures and functions, BNCs enhance drug stability, facilitate penetration across the BBB, and promote tumor-specific targeting while minimizing the risk of systemic toxicity. These nanocarriers can be engineered using a wide variety of biomaterials, including cell membranes, liposomes, and polymeric systems. Recent preclinical and early clinical studies suggest that BNCs provide a viable method to increase drug bioavailability and therapeutic activity. However, several translational challenges remain, including formulation stability, immunogenicity, regulatory acceptability, and large-scale manufacturing. This review discusses recent advances in BNCs for GBM treatment, drug-targeting strategies, and the structural hurdles that limit their clinical translation. Furthermore, we examine emerging multimodal approaches that integrate BNCs with immunotherapy and gene therapy to enhance personalized GBM treatment. [ABSTRACT FROM AUTHOR] |
| Βάση Δεδομένων: | Academic Search Index |
καταχωρήστε σχόλιο πρώτοι!